File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Dose-tumor response for carcinoma of cervix: An analysis of 594 patients treated by radiotherapy

TitleDose-tumor response for carcinoma of cervix: An analysis of 594 patients treated by radiotherapy
Authors
Issue Date1993
PublisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygyno
Citation
Gynecologic Oncology, 1993, v. 49 n. 3, p. 311-317 How to Cite?
AbstractThis is a retrospective study of 594 histologically proven carcinomas of the uterine cervix treated with radiotherapy alone between January 1970 and December 1986. The age of this group of patients ranged from 22 to 86 years, and the median age was 57 years. There were 544 (91.6%) patients with squamous carcinoma and 36 (6.1%) with adenocarcinoma. There were 24 (4.0%) patients who were treated by two sessions of intracavitary brachytherapy only using intrauterine tandem and vaginal ovoids; 513 (86.4%) patients received whole pelvis irradiation followed by two sessions of brachytherapy at 1-week intervals, with or without additional boost to the parametrium. The dose to point A ranged from 40 to 100.9 Gy for the patients with stage IB to IIIB disease. The 5- and 10-year survival for stages IB, IIA, IIB, IIIA, and IIIB were 90.0, 82.1, 72.0, 50.0, 51.5, and 86.9, 71.0, 67.5, 41.7, and 46.9%, respectively. There was no long-term survivor for stage IV disease; the median survivals for patients with stages IVA and IVB were 15.2 and 9.3 months, respectively. Dose response was demonstrated for stages IIB and III tumors; dose to point A greater than 85 Gy was associated with better central control (P = 0.0036 and 0.0234, respectively). However, further increase in dose to point A beyond 85 Gy was not associated with improvement in central control (P = 0.3128 and 0.3394, respectively, for stages IIB and III). It was also found that the occurrences of rectosigmoid and bladder complications were correlated with the rectal and point A dose. Thus, for these patients, there is no need to increase the dose to point A beyond 85 Gy so that the risk of radiation sequelae can be cut down.
Persistent Identifierhttp://hdl.handle.net/10722/173183
ISSN
2015 Impact Factor: 4.198
2015 SCImago Journal Rankings: 2.284
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChoy, Den_US
dc.contributor.authorWong, LCen_US
dc.contributor.authorSham, Jen_US
dc.contributor.authorNgan, HYSen_US
dc.contributor.authorMa, HKen_US
dc.date.accessioned2012-10-30T06:28:23Z-
dc.date.available2012-10-30T06:28:23Z-
dc.date.issued1993en_US
dc.identifier.citationGynecologic Oncology, 1993, v. 49 n. 3, p. 311-317en_US
dc.identifier.issn0090-8258en_US
dc.identifier.urihttp://hdl.handle.net/10722/173183-
dc.description.abstractThis is a retrospective study of 594 histologically proven carcinomas of the uterine cervix treated with radiotherapy alone between January 1970 and December 1986. The age of this group of patients ranged from 22 to 86 years, and the median age was 57 years. There were 544 (91.6%) patients with squamous carcinoma and 36 (6.1%) with adenocarcinoma. There were 24 (4.0%) patients who were treated by two sessions of intracavitary brachytherapy only using intrauterine tandem and vaginal ovoids; 513 (86.4%) patients received whole pelvis irradiation followed by two sessions of brachytherapy at 1-week intervals, with or without additional boost to the parametrium. The dose to point A ranged from 40 to 100.9 Gy for the patients with stage IB to IIIB disease. The 5- and 10-year survival for stages IB, IIA, IIB, IIIA, and IIIB were 90.0, 82.1, 72.0, 50.0, 51.5, and 86.9, 71.0, 67.5, 41.7, and 46.9%, respectively. There was no long-term survivor for stage IV disease; the median survivals for patients with stages IVA and IVB were 15.2 and 9.3 months, respectively. Dose response was demonstrated for stages IIB and III tumors; dose to point A greater than 85 Gy was associated with better central control (P = 0.0036 and 0.0234, respectively). However, further increase in dose to point A beyond 85 Gy was not associated with improvement in central control (P = 0.3128 and 0.3394, respectively, for stages IIB and III). It was also found that the occurrences of rectosigmoid and bladder complications were correlated with the rectal and point A dose. Thus, for these patients, there is no need to increase the dose to point A beyond 85 Gy so that the risk of radiation sequelae can be cut down.en_US
dc.languageengen_US
dc.publisherAcademic Press. The Journal's web site is located at http://www.elsevier.com/locate/ygynoen_US
dc.relation.ispartofGynecologic Oncologyen_US
dc.subject.meshActuarial Analysisen_US
dc.subject.meshAdenocarcinoma - Radiotherapyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 And Overen_US
dc.subject.meshCarcinoma, Squamous Cell - Radiotherapyen_US
dc.subject.meshDose-Response Relationship, Radiationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshNeoplasm Stagingen_US
dc.subject.meshRadiotherapy Dosageen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSurvival Analysisen_US
dc.subject.meshUterine Cervical Neoplasms - Pathology - Radiotherapyen_US
dc.titleDose-tumor response for carcinoma of cervix: An analysis of 594 patients treated by radiotherapyen_US
dc.typeArticleen_US
dc.identifier.emailNgan, HYS:hysngan@hkucc.hku.hken_US
dc.identifier.authorityNgan, HYS=rp00346en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1006/gyno.1993.1132en_US
dc.identifier.pmid8314532-
dc.identifier.scopuseid_2-s2.0-0027193699en_US
dc.identifier.volume49en_US
dc.identifier.issue3en_US
dc.identifier.spage311en_US
dc.identifier.epage317en_US
dc.identifier.isiWOS:A1993LJ51200008-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridChoy, D=8663654500en_US
dc.identifier.scopusauthoridWong, LC=7402092003en_US
dc.identifier.scopusauthoridSham, J=7101655565en_US
dc.identifier.scopusauthoridNgan, HYS=34571944100en_US
dc.identifier.scopusauthoridMa, HK=7403095603en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats